 The use of positron emission tomography, PET, with 18F, fluorodeoxyglucose, FDG, has revolutionized the field of oncological imaging, but it suffers from limitations such as low sensitivity and specificity in certain tumor subtypes. Fibroblast activation protein FAP, which is expressed by cancer-associated fibroblasts, CAFs, may hold the key to address these issues. FAP is selectively overexpressed in a vast majority of neoplasms, including epithelial cancers, making it a promising target for molecular imaging and therapy. Several radio-labeled FAP inhibitors, FAP, have been developed for Peru time slash central time imaging and potential theranostic applications. Early results are promising with extensive multidisciplinary clinical research currently underway. This article was authored by Kunal Ramesh Shandekar, Arun Prashant, Saab Hondinjumri, and others. We are article.tv, links in the description below.